1. Scrip
  2. >>Business
  3. >>Strategy

Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas

Teva reported Phase IIb data for its anti-TL1A agent in ulcerative colitis and Crohn’s that the company called transformational and analysts deemed potentially best in class.

Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock

Teva and Sanofi unveiled positive Phase IIb data on 17 December for the TL1A-targeting antibody candidate they are developing to compete against candidates from the same class at Roche and Merck & Co. in inflammatory bowel disease (IBD). On a same-day call, Teva execs asserted that their drug, duvakitug (TEV‘574/SAR447189), has produced “transformational” data in both ulcerative colitis and Crohn’s disease as the partners look ahead to planning a Phase III program.

Key Takeaways
  • Teva reported that the TL1A-targeting antibody it is developing for IBD with Sanofi hit primary endpoints in ulcerative colitis and Crohn’s in a Phase IIb trial.

In the RELIEVE UCCD study, duvakitug met the primary endpoint of clinical remission in UC with both doses tested, 450mg...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.